+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030- Product Image
Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030- Product Image
Sale

Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080650
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Tenofovir Disoproxil Fumarate tablets have become a cornerstone in contemporary antiviral therapy, recognized for their potent inhibition of HIV and Hepatitis B viral replication. As a prodrug formulation engineered to improve bioavailability and tolerability, this compound has earned endorsement from global health authorities for its consistent safety profile and high barrier to resistance. In light of expiring patents, the landscape has seen an expansion of generic entrants, driving increased accessibility and affordability across diverse healthcare systems.

In response to these developments, this executive summary synthesizes the latest industry trends, regulatory developments, and patient-centered innovations influencing the TDF tablet ecosystem. By tracing the journey from raw material sourcing through advanced formulation techniques to evolving patient adherence platforms, stakeholders will gain a holistic view of the forces shaping future therapeutic strategies. With a focus on actionable intelligence, the report offers a strategic foundation for manufacturers, payers, and healthcare providers seeking to navigate complexity and optimize outcomes in the dynamic antiviral treatment arena.

Rapid Technological and Policy Transformations Redefining Patient Access and Therapeutic Efficacy for Tenofovir Disoproxil Fumarate Tablets Worldwide

Over the past decade, rapid advancements in drug delivery technologies and shifts in healthcare policy have fundamentally altered patient access to Tenofovir Disoproxil Fumarate tablets. Novel formulation approaches-including nanoparticle encapsulation and extended-release matrices-are enhancing pharmacokinetic profiles, reducing pill burden, and improving adherence among key patient populations. Simultaneously, digital health solutions such as remote monitoring platforms and mobile adherence applications are bridging gaps in care coordination, particularly in resource-limited settings.

Moreover, regulatory bodies are revising approval pathways to expedite access to generics and biosimilar analogs, while global procurement mechanisms are strengthening centralized tenders to leverage economies of scale. These policy realignments, coupled with heightened emphasis on cost-containment, are redefining competitive dynamics and compelling manufacturers to adopt leaner operational models. As a result, both established pharmaceutical players and emerging biotechnology firms must continuously innovate to maintain therapeutic relevance and respond proactively to evolving market demands.

Assessing the Combined Influence of United States Tariffs on Manufacturing Costs, Supply Chains, and Patient Access to Tenofovir Disoproxil Fumarate Tablets

The introduction of targeted United States tariffs on active pharmaceutical ingredients has created a ripple effect across the Tenofovir Disoproxil Fumarate supply chain. With a significant portion of raw materials imported from Asia, manufacturers have experienced increased input costs, prompting them to explore alternative sourcing arrangements and negotiate new trade agreements. In addition, logistical bottlenecks at key ports of entry have led to intermittent delays, underscoring the need for diversified warehousing and contingency planning.

Furthermore, higher manufacturing expenses are gradually being passed downstream, placing pressure on distribution partners and healthcare providers to reassess procurement strategies. In tandem, patient advocacy groups have begun lobbying for policy exemptions to safeguard affordability and uninterrupted access, particularly for underserved communities. As a result of these multifaceted challenges, organizations are prioritizing supply chain resilience and cost mitigation measures-ranging from dual-sourcing frameworks to strategic stockpiling-to ensure the continuous availability of TDF tablets.

Deep Dive into Critical Segmentation Drivers Influencing Dosage Strengths, Product Types, Treatment Regimens, Distribution Channels, Indications, and Packaging

A multidimensional examination of market segmentation reveals critical insights into how distinct product and patient categories influence commercial and clinical strategies. When considering dosage strength variations, the 150 mg formulation remains a preferred choice for maintenance therapy in specific patient profiles, while the 300 mg option continues to dominate new treatment initiations due to its broader application across both HIV prophylaxis and treatment. The distinction between branded and generic offerings further drives pricing strategies and formulary negotiations, with generic versions enabling wider reimbursement coverage.

Treatment regimen segmentation-whether monotherapy or combination therapy-affects prescribing behavior and adherence outcomes, as combination formulations often yield simplified dosing schedules and enhanced viral suppression. Distribution channels such as hospital settings, online pharmacies, and community drug stores each present unique logistical considerations and patient engagement opportunities. Clinical indications for Hepatitis B, HIV prophylaxis, and HIV treatment necessitate tailored patient education and support programs. Meanwhile, packaging formats-ranging from traditional bottles to unit-dose strips-impact shelf life, patient compliance, and regulatory labeling requirements. By integrating these segmentation drivers, stakeholders can formulate targeted strategies that align product design with evolving therapeutic demands.

Exploring Distinct Regional Dynamics and Unmet Needs Shaping Tenofovir Disoproxil Fumarate Tablet Adoption in the Americas EMEA and Asia-Pacific Regions

Regional dynamics exert a profound influence on how Tenofovir Disoproxil Fumarate tablets are adopted and reimbursed across global healthcare systems. In the Americas, a combination of strong regulatory harmonization among leading markets and comprehensive public health initiatives has facilitated broad access to both branded and generic formulations. However, reimbursement complexities in certain jurisdictions continue to challenge equitable distribution, driving stakeholders to explore value-based pricing models and outcome-oriented contracting.

In Europe, the Middle East & Africa, diverse regulatory frameworks and varied procurement capabilities shape market entry strategies. While some European markets leverage centralized tenders to streamline access, regions in the Middle East and Africa often contend with fragmented supply chains and limited healthcare infrastructure. Collaborative public-private partnerships are emerging to strengthen distribution networks and patient support programs. Meanwhile, in Asia-Pacific, rapid regulatory approvals in key economies are fostering accelerated generic uptake, although market penetration rates differ substantially between mature healthcare systems and emerging markets. Tailored engagement strategies that reflect each region’s policy environment and patient needs are therefore essential.

Insights into Leading Pharmaceutical Companies Advancing Research, Partnerships, and Market Positioning for Tenofovir Disoproxil Fumarate Tablets

Leading pharmaceutical organizations continue to advance the Tenofovir Disoproxil Fumarate segment through a combination of targeted research collaborations and strategic licensing agreements. Multinational companies have invested in extended-release prodrug development programs, while select generic manufacturers are optimizing production efficiencies to reduce unit costs without sacrificing quality. Joint ventures between originator firms and regional producers have proven particularly effective at accelerating regulatory submissions and local market penetration.

In parallel, several emerging biotech firms are exploring next-generation nucleotide analogs, aiming to differentiate their pipelines through enhanced safety profiles and novel delivery mechanisms. These upstarts often rely on co-development partnerships with established drugmakers to leverage existing manufacturing infrastructure. Across the competitive spectrum, alliances that integrate real-world evidence studies and patient adherence platforms have become a focal point for building the value proposition of TDF tablets and strengthening payer relationships.

Actionable Recommendations and Strategic Roadmaps for Industry Leaders to Enhance Tenofovir Disoproxil Fumarate Tablet Development and Access Strategies

To capitalize on the evolving TDF landscape, industry leaders should prioritize the establishment of resilient dual-sourcing arrangements for critical raw materials and engage in proactive policy dialogues to mitigate the impact of potential trade disruptions. Strengthening collaborations with digital health vendors can streamline patient adherence monitoring, while piloting extended-release formulations may unlock new therapeutic niches and improve convenience for long-term users.

Moreover, manufacturers are advised to refine package differentiation strategies-balancing environmental sustainability with compliance imperatives-and to negotiate value-based agreements that align reimbursement with clinical outcomes. Engaging in regional consortiums and targeted educational initiatives will further enhance stakeholder alignment, ensuring that formulary committees and healthcare providers appreciate the full spectrum of therapeutic benefits. Through these combined approaches, organizations can drive sustained growth and foster durable patient partnerships.

Rigorous Mixed Methods Framework Integrating Quantitative Data Analysis, Qualitative Stakeholder Interviews, and Literature Review to Ensure Research Depth

This analysis employs a rigorous mixed-methods framework to deliver comprehensive insight into the Tenofovir Disoproxil Fumarate market environment. The research process begins with quantitative data analysis drawn from peer-reviewed literature, regulatory filings, and public procurement databases to identify key trends in formulation, pricing, and distribution.

Complementing this, qualitative stakeholder interviews with clinicians, procurement officers, and supply chain managers furnish context around real-world challenges and emergent best practices. A systematic literature review validates primary findings and uncovers latent opportunities for innovation. Data triangulation ensures that diverse information sources converge into a cohesive narrative, while internal expert advisory panels review conclusions for accuracy and relevance. This methodological rigor underpins the strategic imperatives and recommendations presented throughout the report.

Summarizing Key Insights and Strategic Imperatives to Guide Optimized Development and Deployment of Tenofovir Disoproxil Fumarate Tablets

The intersection of technological advancements, evolving regulatory landscapes, and dynamic patient needs has created a multifaceted environment for Tenofovir Disoproxil Fumarate tablet stakeholders. Segmentation by dosage strengths, product types, and distribution channels reveals targeted opportunities for differentiation, while regional analyses underscore the importance of tailored market entry strategies. Industry players that embrace collaborative research models, digital health integrations, and resilient supply networks are best positioned to address affordability and adherence challenges.

Strategic imperatives highlighted in this summary-ranging from adaptive sourcing frameworks to outcome-based contracting and patient-centric packaging-provide a blueprint for aligning organizational capabilities with shifting global demands. By leveraging these insights, stakeholders can refine their development pipelines, streamline commercialization pathways, and ultimately deliver improved clinical outcomes for individuals relying on TDF therapy.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Dosage Strength
    • 150 Mg
    • 300 Mg
  • Product Type
    • Branded
    • Generic
  • Treatment Regimen
    • Combination Therapy
    • Monotherapy
  • Distribution Channel
    • Hospital
    • Online
    • Pharmacy
  • Indication
    • Hepatitis B Treatment
    • Hiv Prophylaxis
    • Hiv Treatment
  • Packaging Type
    • Bottle
    • Strip
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Hetero Drugs Limited
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
  • Lupin Limited
  • Emcure Pharmaceuticals Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growth of generic TDF tablets driving dramatic price reductions and increased accessibility
5.2. Advancements in fixed-dose combination therapies including tenofovir disoproxil fumarate for simplified HIV treatment
5.3. Rising investments in R&D for novel tenofovir formulations targeting improved renal safety profiles
5.4. Regulatory approvals for new tenofovir disoproxil fumarate generics accelerating market expansion in emerging economies
5.5. Increasing adoption of TDF-based pre-exposure prophylaxis programs boosting demand across high-risk populations
5.6. Strategic partnerships between biotech firms and CROs enhancing clinical pipeline for tenofovir analog development
5.7. Market shift towards multi-year procurement contracts for TDF tablets to secure long-term supply stability
5.8. Surge in competitive marketing campaigns emphasizing TDF tablet efficacy in HBV co-infection management
5.9. Emergence of local manufacturing hubs reducing import reliance and optimizing tenofovir distribution logistics
5.10. Impact of raw material price volatility on tenofovir disoproxil fumarate tablet production costs and margins
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tenofovir Disoproxil Fumarate Tablets Market, by Dosage Strength
8.1. Introduction
8.2. 150 Mg
8.3. 300 Mg
9. Tenofovir Disoproxil Fumarate Tablets Market, by Product Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Tenofovir Disoproxil Fumarate Tablets Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Tenofovir Disoproxil Fumarate Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Hospital
11.3. Online
11.4. Pharmacy
12. Tenofovir Disoproxil Fumarate Tablets Market, by Indication
12.1. Introduction
12.2. Hepatitis B Treatment
12.3. Hiv Prophylaxis
12.4. Hiv Treatment
13. Tenofovir Disoproxil Fumarate Tablets Market, by Packaging Type
13.1. Introduction
13.2. Bottle
13.3. Strip
14. Americas Tenofovir Disoproxil Fumarate Tablets Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. Viatris Inc.
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Cipla Limited
17.3.5. Aurobindo Pharma Limited
17.3.6. Hetero Drugs Limited
17.3.7. Sun Pharmaceutical Industries Limited
17.3.8. Zydus Lifesciences Limited
17.3.9. Lupin Limited
17.3.10. Emcure Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHAI
FIGURE 28. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 29. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHCONTACTS
FIGURE 30. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 150 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 150 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 300 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 300 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HEPATITIS B TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HEPATITIS B TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STRIP, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STRIP, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 77. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 78. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 79. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 82. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 83. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 89. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 90. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 91. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 94. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 95. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 151. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 152. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 153. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 156. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 157. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 163. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 164. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 165. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 168. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 169. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 187. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 192. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 193. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 198. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 199. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 200. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 201. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 204. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 205. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 247. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 252. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 253. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 271. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 272. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 273. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 276. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 277. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 282. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 283. FINLAND TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 284. FINLAND TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-203

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tenofovir Disoproxil Fumarate Tablets market report include:
  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Hetero Drugs Limited
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
  • Lupin Limited
  • Emcure Pharmaceuticals Limited

Related Topics

Related Reports

Tenofovir Disoproxil Fumarate (CAS 202238-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Tenofovir Disoproxil Fumarate (CAS 202238-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Tenofovir Disoproxil Global Market Report 2025 - Product Image

Tenofovir Disoproxil Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Tenofovir (CAS 147127-20-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Tenofovir (CAS 147127-20-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
HIV Drugs Market Report 2025 - Product Image

HIV Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.